Letter: Why we should support the Equity in Neuroscience and Alzheimer’s Clinical Trials Act

Posted 4/19/22

While nearly everyone is likely to be familiar with Alzheimer’s disease because of its skyrocketing prevalence, many people don’t realize that it disproportionately affects older …

This item is available in full to subscribers.

Please log in to continue

Username
Password
Log in

Don't have an ID?


Print subscribers

If you're a print subscriber, but do not yet have an online account, click here to create one.

Non-subscribers

Click here to see your options for becoming a subscriber.

If you made a voluntary contribution in 2021-2022, but do not yet have an online account, click here to create one at no additional charge. VIP Digital Access includes access to all websites and online content.


Our print publications are advertiser supported. For those wishing to access our content online, we have implemented a small charge so we may continue to provide our valued readers and community with unique, high quality local content. Thank you for supporting your local newspaper.

Letter: Why we should support the Equity in Neuroscience and Alzheimer’s Clinical Trials Act

Posted

While nearly everyone is likely to be familiar with Alzheimer’s disease because of its skyrocketing prevalence, many people don’t realize that it disproportionately affects older Black and Hispanic Americans versus older Whites. Despite being more likely to have the disease, decades of Alzheimer’s research has not included sufficient numbers of Blacks or Hispanics — not to mention Asian Americans/Pacific Islanders and Native Americans — to be representative of the U.S. population.

The Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act is bipartisan legislation that would increase the participation of underrepresented populations in Alzheimer’s clinical trials by expanding education and outreach to these populations. The ENACT Act would create a path to better Alzheimer’s care and address shortcomings in the way research and care is currently being delivered to underrepresented communities.

Please join me and the Alzheimer’s Association in asking Representative Perlmutter to support the Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act. Equality in Alzheimer’s care is obtainable through increasing diversity in dementia care, preparing the workforce to care for a racially and ethnically diverse population of older adults, and engaging, recruiting, and retaining diverse populations in Alzheimer’s research and clinical trials.

Lisa Solano,
Arvada

Comments

Our Papers

Ad blocker detected

We have noticed you are using an ad blocking plugin in your browser.

The revenue we receive from our advertisers helps make this site possible. We request you whitelist our site.